{
    "clinical_study": {
        "@rank": "38428", 
        "arm_group": [
            {
                "arm_group_label": "Raltegravir + 2 NRTIs", 
                "description": "Raltegravir is an integrase inhibitor.\nNucleoside Reverse Transcriptase Inhibitor (NRTIs)"
            }, 
            {
                "arm_group_label": "NNRTI + 2 NRTIs", 
                "description": "Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine"
            }, 
            {
                "arm_group_label": "PI + 2 NRTIs", 
                "description": "Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir"
            }, 
            {
                "arm_group_label": "Other Second Line Therapies", 
                "description": "Other second line therapies could include: enfuvirtide, maraviroc, raltegravir + PI"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, longitudinal observational study of adult human immunodeficiency\n      virus (HIV) participants at academic and community-based practices in the United States who\n      are switching from first-line to second-line therapy. The study's primary hypothesis is that\n      HIV participants switching to raltegravir-based regimens will have better Medical Outcomes\n      Study-HIV (MOS-HIV) Health Survey scores than participants switched to non-nucleoside\n      reverse transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens."
        }, 
        "brief_title": "Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Human Immunodeficiency Virus", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of HIV\n\n          -  Switching antiretroviral regimen(s) for the first time at the start of the study\n\n        Exclusion Criteria:\n\n          -  Currently pregnant\n\n          -  Presence of active tuberculosis, Hepatitis B, and/or Hepatitis C and receiving\n             treatment for the condition(s) during the study period\n\n          -  Presence of active pneumonia or other signs of opportunistic infections at the start\n             of the study\n\n          -  Currently participating in a clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "HIV patients at academic and community-based practices in the United States"
            }
        }, 
        "enrollment": {
            "#text": "134", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814722", 
            "org_study_id": "0518-266"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "HIV Protease Inhibitors", 
                "Reverse Transcriptase Inhibitors", 
                "Anti-Retroviral Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "HIV Infections", 
            "Anti-HIV Agents", 
            "Anti-Retroviral Agents", 
            "Nucleoside Reverse Transcriptase Inhibitors", 
            "Non-nucleoside Reverse Transcriptase Inhibitor", 
            "Protease inhibitors"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "number_of_groups": "4", 
        "official_title": "Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Comparison of Medical Outcomes Study-HIV (MOS-HIV) Health Survey Scores", 
            "safety_issue": "No", 
            "time_frame": "Week 4 Follow-up"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814722"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Depression, Anxiety, and Stress Scale (DASS-21)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4 Follow-up"
            }, 
            {
                "measure": "Change from Baseline in HIV Symptom Index (HIV-SI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4 Follow-up"
            }, 
            {
                "measure": "Change from Baseline in Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4 Follow-up"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}